Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SurVaxM as an Interception Agent in Patients at High Risk for Lung Cancer
NCT07169617Phase 2Not yet recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2026
- Primary completion
- Mar 2029
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SurVaxM in lung cancer, sponsored by National Cancer Institute. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
SurVaxM
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT07169617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07169617.